The preventive Effectiveness of Rituximab in Pediatric Autoimmune and Inflammatory CNS Diseases Relapse: an Iranian Experience
Iranian Journal of Child Neurology,
Vol. 16 No. 3 (2022),
16 July 2022
,
Page 167-182
https://doi.org/10.22037/ijcn.v16i3.29322
Abstract
Objectives
To determine the effectiveness of Rituximab (RTX) therapy as the first therapeutic choice for the long-term prevention of secondary relapse in children with Autoimmue Neurological Disease (AIND) had relapse after primary treatment with immunosuppressive agents other than RTX.
Materials & Methods
We conducted a single-center retrospective study of 9 consecutive pediatric patients (≤ 18 years old) registered on Autoimmune and Demyelinating Disorders Database (ADDD) of Mofid Children Hospital, from 2012 to 2016 and experienced relapse following therapeutic interventions with immunosuppressive agents other than RTX.
Result
A remarkable reduction of 94.13% (p=0.015) occurred in annualized relapse rate (ARR) as a clinical indicator of therapeutic efficacy comparing before and after initiating RTX therapy.
Conclusion
Rituximab is an effective drug in relapse prevention of AIND whenadministrated to patients for whom initial treatment with other immunosuppressive agents fail. POWER OF EVIDENCE: This study represents Class IV evidence that RTX therapy significantly reduces ARR in pediatric AIND including DDCNS.
- Rituximab
- CNS demyelinating diseases
- Immunological disease
- efficacy
How to Cite
References
- Eibel H, Kraus H, Sic H, Kienzler AK, Rizzi M. B cell biology: an overview. Curr Allergy Asthma Rep 2014;14:434.
- Krumbholz, M. and E. Meinl. "B cells in MS and NMO: pathogenesis and therapy." Semin Immunopathol 2014; 36(3): 339-350.
- Seyfizadeh, N., N. Seyfizadeh, J. Hasenkamp and S. Huerta-Yepez . "A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections." Crit Rev Oncol Hematol 2016; 97: 275-290.
- Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs 2002;13(2):3–10.
- Grillo-Lo´ pez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999;26(14):66 –73.
- Quartier P, Brethon B, Philippet P, et al. Treatment of childhood auto-immune hemolytic anemia with rituximab. Lancet 2001;358:1511–1513
- Faurschou M, Hasselbalch HC, Nielsen OJ. Sustained remission of
platelet counts following monoclonal anti-CD20 antibody therapy in
two cases of idiopathic autoimmune thrombocytopenia and neutrope-nia. Eur J Haematol 2001;66:408 – 411.
- Pranzatelli MR,Tate ED, Travelstead AL, Longee D.Immunologic and Clinical Responses to Rituximab in a Child With Opsoclonus-Myoclonus Syndrome.Pediatrics 2005;115(1):115-119.
- Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients
with rheumatoid arthritis treated with B lymphocyte depletion. Ann
Rheum Dis 2002;61:883– 888.
- Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence based medicine. Plast Reconstr Surg 2011;128(1):305–310.
- Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485–1489.
- Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007;6:805–815.
- Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system Demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013;19: 1261-1267.
- Matthay KK , Blaes F , Hero B , et al . Opsoclonus myoclonus syndrome in neuroblastoma: a report· from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa , Italy , 2004 . Cancer Letters 2005; 228:275-282.
- Whittam DH, Tallantyre EC, Jolles S, et al. Rituximab in neurological disease: principles , evidence and practice. Practical Neurology 2019;19:5-20.
-Sweeney M.Autoimmune Neurologic Diseases in Children. Semin Neurol 2018;38:355–370
- Lancaster E, Dalmau J . Neuronal autoantigens – pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012;8: 380–390.
- Banwell B, Tenembaum S, Lennon VA, et al. Neuromyelitis optica IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008;70(05):344–352.
- Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364(9451):2106–2112.
- Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202(4):473–477.
-Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85(2):177–189.
- Etemadifar M, Nasr Z, Khalili B, Taherioun M, Vosoughi R. Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. Mult Scler Int 2015;2015:174720.
- Pandit L, Asgari N, Apiwattanakul M, et al. Demographic and clinical features of neuromyelitis optica: a review. Mult Scler 2015;21(7):845–853.
- Collongues N, Marignier R, Zéphir H, et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010; 74(09):736–742.
- Chitnis T, Ness J, Krupp L, et al. Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report. Neurology 2016;86(03):245–252.
- Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics 2008;122 (05):e1039–e1047
- Yamaguchi Y, Torisu H, Kira R, et al. A nationwide survey of pediatric acquired demyelinating syndromes in Japan. Neurology 2016;87(19): 2006–2015.
- Tenembaum S, Chitnis T, Nakashima I, et al. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology 2016; 87(2):59–66.
- Zarei S, Eggert J, Franqui-Dominguez L, et al. Comprehensive review of neuromyelitis optica and clinical characteristics of neuromyelitis optica patients in Puerto Rico. Surg Neurol Int 2018;9:242.
- Nosadini M, Alper G, Riney CJ, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 2016;3(1):e188.
- Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014;83(2):142–150.
- Longoni G, Banwell B, Filippi M, Yeh EA. Rituximab as a first-line preventive
treatment in pediatric NMOSDs: preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm 2014;1(4):e46.
- Makhani N, Brenton JN, Banwell B. Acquired Disorders Affecting the White Matter. In: Swaiman KF, Ashwal S, Ferriero D, Schor NF, Finkel RS, Gropman AL, Pearl PL, Shevell MI, editors. Swaiman’s Pediatric Neurology: Principles and Practice. New York: Elsevier Inc; 2017. pp. e1734-e1736.
- Chitnis T. Pediatric Central Nervous System Demyelinating Diseases. CONTINUUM: Multiple Sclerosis and other CNS Inflammatory Diseases 2019;25(3): 793-814 .
- Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in
seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation 2012;9:14.
-Kitley J, Woodhall M, Waters P, et al. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 2012;79(12):1273–1277.
- Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014;71(3):276–283.
- Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014;82(6):474–481.
- Watanabe A, Matsushita T, Doi H, et al. Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and -negative multiple sclerosis patients. J Neurol Sci 2009;281(1–2): 34–40.
- Ringelstein M, Kleiter I, Ayzenberg I, et al. Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Mult Scler 2014;20(5):617–620.
- Banwell B, Kennedy J, Sadovnick D, et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009;72(3): 232–239.
-Blaes F, Dharmalingam B. Childhood opsoclonus-myoclonus syndrome: diagno-sis
and treatment. Expert Rev Neurother 2016 ;16(6):641-648.
-Alexopoulos H, Biba1 A, Dalakas MS .Anti-B-Cell Therapies in Autoimmune Neurological Diseases:Rationale and Efficacy Trials. Neurotherapeutics 2016; 13:20–33
- Kosmidis ML, Dalakas MS.Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord 2010; 3(2): 93-105.
- Dalakas MC. B-cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther 2006;112: 57-70.
-Birnbaum J, Kerr D. Optic neuritis and recurrent myelitis in a woman with
systemic lupus erythematosus. Nat Clin Pract Rheumatol 2008;4(7):381–386.
-Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster
E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil
retrospective analysis of 24 patients. Arch Neurol 2009;66(9):1128–1133.
-Chay J, Donovan P, Cummins L, Kubler P, Pillans P. Experience with lowdose rituximab in off-label indications at two tertiary hospitals. Intern Med J
;43(8):871–882.
- Gao F , Chai B , Gu C· , Wu R , Dong T , Yao Y , Zhang Y. Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol 2019 19(1):36.
- Borisow N, Mori M, Kuwabara S, Scheel M, Paul F. Diagnosis and treatment of
NMO Spectrum Disorder and MOG-Encephalomyelitis.Front Neurol 2018; 23(9):888.
- Cree BAC, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64:1270–1272.
- Pellkofer HL, Krumbholz M, Berthele A, Hemmer B, Gerdes LA, Havla J, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76:1310-1315.
- Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of
relapse and treatment failure rates among patients with neuromyelitis optica: Multicenter study of treatment effcacy. JAMA Neurol 2014;71:324 330.
- Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 2013;70:1110-1117.
- Jacob, A. et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443–1448.
- Kim, S.-H., Kim, W., Li, X. F., Jung, I.-J. & Kim, H. J. Repeated treatment with Rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch. Neurol 2011; 68: 1412–1420.
- Bedi, G. S. et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011; 17: 1225–1230.
- Greenberg, B. M. et al. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 2012; 18: 1022–1026 .
- Pranzatelli MR, Tate ED, Travelstead AL, Barbosa J, Bergamini RA, Civitello L, Franz DN, Greffe BS, Hanson RD, Hurwitz CA, Kalinyak KA, Kelfer H, Khakoo Y, Mantovani JF, Nicholson SH, Sanders JM, Wegner S. Rituximab Adjunctive Therapy for Opsoclonus Myoclonus syndrome. J Pediatr Hematol Oncol 2006; 28(9):585-593.
- Dale RC, Brilot F, Duffy LV, Twilt M, Waldman AT, Narula S, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology 2014; 83(2):142-150.
- Pranzatelli MR, Tate ED, McGee NR. Demographic, clinical, and immunologic Features of 389 children with Opsoclonus Myoclonus syndrome: A cross-sectional study. Front Neurol 2017 Sep 11;8:468.
- Abstract Viewed: 270 times